247 related articles for article (PubMed ID: 36165526)
1. Clinical Consideration for Mesenchymal Stem Cells in Treatment of COVID-19.
Wu KH; Chao YH; Weng TF; Li JP
Curr Pharm Des; 2022; 28(36):2991-2994. PubMed ID: 36165526
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal Stem Cells in the Treatment of COVID-19.
Guo BC; Wu KH; Chen CY; Lin WY; Chang YJ; Lee TA; Lin MJ; Wu HP
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834246
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19.
Li JP; Wu KH; Chao WR; Lee YJ; Yang SF; Chao YH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897770
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
Ringdén O; Moll G; Gustafsson B; Sadeghi B
Front Immunol; 2022; 13():839844. PubMed ID: 35371003
[TBL] [Abstract][Full Text] [Related]
5. Expediting Molecular Translational Approach of Mesenchymal Stem Cells in COVID-19 Treatment.
Balaji Easwaran V; Satarker S; V Gujaran T; John J; Veedu AP; George KT; Purayil DK; Beegum F; Mathew A; Vibhavari R; Chaudhari SS; Pai KSR
Curr Stem Cell Res Ther; 2023; 18(5):653-675. PubMed ID: 36424799
[TBL] [Abstract][Full Text] [Related]
6. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
Can A; Coskun H
Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal Stem Cells Therapy for COVID-19: From Basic Research to Clinical Trial.
Tao YC; Chen EQ
Curr Stem Cell Res Ther; 2024; 19(1):55-62. PubMed ID: 36654468
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
Moradinasab S; Pourbagheri-Sigaroodi A; Zafari P; Ghaffari SH; Bashash D
Int Immunopharmacol; 2021 Aug; 97():107694. PubMed ID: 33932694
[TBL] [Abstract][Full Text] [Related]
9. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
[TBL] [Abstract][Full Text] [Related]
10. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
Gu J; Zhao Q; Han Z; Han Z
Curr Stem Cell Res Ther; 2021; 16(3):277-285. PubMed ID: 32729428
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.
Yao W; Shi L; Zhang Y; Dong H; Zhang Y
Stem Cell Res Ther; 2022 Mar; 13(1):124. PubMed ID: 35321737
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.
Chen L; Qu J; Kalyani FS; Zhang Q; Fan L; Fang Y; Li Y; Xiang C
Cell Mol Life Sci; 2022 Feb; 79(3):142. PubMed ID: 35187617
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19.
Rocha JLM; de Oliveira WCF; Noronha NC; Dos Santos NCD; Covas DT; Picanço-Castro V; Swiech K; Malmegrim KCR
Stem Cell Rev Rep; 2021 Feb; 17(1):71-93. PubMed ID: 32895900
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K
Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Gorman E; Millar J; McAuley D; O'Kane C
Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
[No Abstract] [Full Text] [Related]
16. Immunomodulation and Regenerative Capacity of MSCs for Long-COVID.
Loke XY; Imran SAM; Tye GJ; Wan Kamarul Zaman WS; Nordin F
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830303
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment.
Raza SS; Khan MA
Cytotherapy; 2022 Aug; 24(8):755-766. PubMed ID: 35880307
[TBL] [Abstract][Full Text] [Related]
18. Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Severe COVID-19 Patients.
Heidari F; Heidari R; Sabet MN; Hamidieh AA; Saltanatpour Z
Curr Stem Cell Res Ther; 2024; 19(5):644-652. PubMed ID: 37073149
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment.
Fang Y; Lao P; Tang L; Chen J; Chen Y; Sun L; Tan W; Fan X
Cell Transplant; 2023; 32():9636897231184611. PubMed ID: 37395459
[TBL] [Abstract][Full Text] [Related]
20. Challenges of mesenchymal stem cells in the clinical treatment of COVID-19.
Li L; Zhang X; Wu Y; Xing C; Du H
Cell Tissue Res; 2024 Jun; 396(3):293-312. PubMed ID: 38512548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
